It is noteworthy that in the DIPG trial, the GD2-CAR contains two signaling domains, 4-1BB and CD3ζ, whereas in the neuroblastoma trial, the GD2-CAR contains three signaling domains, including CD28, 4-1BB, and CD3ζ. The gene discussed is CD247; the disease is neuroblastoma.